サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1775000

悪性神経膠腫治療薬の世界市場

Malignant Glioma Therapeutics

出版日
ページ情報
英文 383 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
悪性神経膠腫治療薬の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 383 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

悪性神経膠腫治療薬の世界市場は2030年までに29億米ドルに達する

2024年に17億米ドルと推定される悪性神経膠腫治療薬の世界市場は、2024年から2030年にかけてCAGR 9.6%で成長し、2030年には29億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである多形膠芽腫手術は、CAGR 11.3％を記録し、分析期間終了時には9億2,620万米ドルに達すると予測されます。多形膠芽腫放射線療法分野の成長率は、分析期間中CAGR 7.1%と推定されます。

米国市場は4億5,020万米ドル、中国はCAGR13.4％で成長予測

米国の悪性神経膠腫治療薬市場は、2024年に4億5,020万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億9,160万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.7%と8.6%と予測されています。欧州では、ドイツがCAGR約7.6%で成長すると予測されています。

世界の悪性神経膠腫治療薬市場- 主要動向と促進要因のまとめ

悪性神経膠腫治療薬が重要性を増している理由

多形膠芽腫（GBM）、星細胞腫、乏突起膠腫などの悪性神経膠腫は、最も侵攻性が高く治療抵抗性の脳腫瘍のひとつです。限られた生存率、再発リスク、および治療戦略の改善の必要性により、神経膠腫治療のための新規薬剤、精密医療、および免疫療法に基づく解決策を開発するための研究努力が推し進められています。

標的治療、遺伝子治療、腫瘍溶解性ウイルス治療の進歩により、患者の生存率を延ばし、QOLを高める可能性のある新たな治療アプローチが出現しつつあります。神経腫瘍学研究における政府のイニシアチブ、民間投資、および学術的共同研究は、薬剤開発パイプラインを加速させています。

イノベーションはどのように悪性神経膠腫治療薬のパフォーマンスを高めているのか？

創薬におけるAIの統合、CRISPR遺伝子編集技術、個別化腫瘍プロファイリングは神経膠腫治療に革命をもたらしています。CAR-T細胞療法と免疫チェックポイント阻害剤は臨床試験で有望な結果を示しており、健康な脳組織へのダメージを最小限に抑える標的アプローチを提供しています。

さらに、電磁波を用いてがん細胞の分裂を阻害する革新的な治療法である腫瘍治療フィールド（TTFields）は、化学療法や放射線療法を補完する治療法として規制当局の承認を得つつあります。ナノテクノロジーを駆使した血液脳関門透過技術も薬物デリバリー効率を向上させ、より効果的な神経膠腫治療を可能にしています。

主な市場促進要因は何か？

悪性神経膠腫の発生率の上昇、研究投資の増加、精密腫瘍学の進歩が市場拡大の原動力となっています。膠芽腫患者の予後を改善する治療法の緊急の必要性が、バイオテクノロジー企業や製薬企業に次世代治療法の開発を促しています。

FDAやEMAなどの規制機関は、革新的な神経膠腫治療薬にファストトラック指定や希少疾病用医薬品の承認を与え、有望な薬剤の市場参入を加速させています。臨床試験ネットワークと患者中心の研究資金の拡大も、新しい神経膠芽腫治療のパイプラインを強化しています。

さらに、神経膠腫の早期発見と治療計画におけるAIを活用した診断の役割の増加は、治療成績を向上させています。免疫療法、放射線療法、高精度ドラッグデリバリーの組み合わせを含むマルチモーダル治療アプローチの統合は、神経膠腫治療の大幅な進歩を促進すると予想されます。

どのような課題と将来の機会が存在するか？

課題には、高い治療費、薬剤耐性、治療開発を困難にしている神経膠腫の複雑な性質が含まれます。血液脳関門は依然として大きなハードルであり、多くの薬剤の有効性を制限しています。しかし、新興のナノテクノロジーに基づくドラッグデリバリーシステム、AIに支援された精密腫瘍学、画期的な免疫療法は、より効果的で個別化された神経膠腫治療の機会を提示しています。非侵襲的早期発見ツールやAI主導の臨床意思決定への拡大は、市場をさらに変革する可能性があります。

セグメント

治療（多形膠芽腫手術、多形膠芽腫放射線療法、多形膠芽腫化学療法、多形膠芽腫標的療法、多形膠芽腫腫瘍治療領域療法、多形膠芽腫免疫療法）、薬剤（テモゾロミド製剤、ベバシズマブ製剤、ロムスチン製剤、カームスチンウエハー製剤、その他の多形膠芽腫治療薬）、エンドユーザー（病院エンドユーザー、クリニックエンドユーザー、外来手術センターエンドユーザー）

調査対象企業の例

  • AbbVie Inc.
  • Aivita Biomedical
  • Amgen Inc.
  • Azurity Pharmaceuticals, Inc.
  • Bayer AG
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb Company
  • Chimerix
  • Denovo Biopharma
  • Epitopoietic Research Corporation
  • F. Hoffmann-La Roche Ltd
  • Laminar Pharma
  • Merck & Co., Inc.
  • Northwest Therapeutics
  • Novocure
  • Pfizer Inc.
  • Plus Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBL Therapeutics

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31964

Global Malignant Glioma Therapeutics Market to Reach US$2.9 Billion by 2030

The global market for Malignant Glioma Therapeutics estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Glioblastoma Multiforme Surgery, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$926.2 Million by the end of the analysis period. Growth in the Glioblastoma Multiforme Radiation Therapy segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$450.2 Million While China is Forecast to Grow at 13.4% CAGR

The Malignant Glioma Therapeutics market in the U.S. is estimated at US$450.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.6 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global Malignant Glioma Therapeutics Market - Key Trends & Drivers Summarized

Why Is Malignant Glioma Therapeutics Gaining Importance?

Malignant gliomas, including glioblastoma multiforme (GBM), astrocytomas, and oligodendrogliomas, are some of the most aggressive and treatment-resistant brain tumors. Limited survival rates, recurrence risks, and the need for improved therapeutic strategies are pushing research efforts to develop novel drugs, precision medicine, and immunotherapy-based solutions for glioma treatment.

With advancements in targeted therapy, gene therapy, and oncolytic virus therapy, new treatment approaches are emerging that could extend patient survival rates and enhance quality of life. Government initiatives, private investments, and academic collaborations in neuro-oncology research are accelerating drug development pipelines.

How Are Innovations Enhancing the Performance of Malignant Glioma Therapeutics?

The integration of AI in drug discovery, CRISPR gene-editing technology, and personalized tumor profiling is revolutionizing glioma treatment. CAR-T cell therapy and immune checkpoint inhibitors are demonstrating promising results in clinical trials, offering targeted approaches that minimize damage to healthy brain tissue.

Additionally, tumor-treating fields (TTFields), an innovative therapy that disrupts cancer cell division using electromagnetic waves, is gaining regulatory approval as a complementary treatment to chemotherapy and radiation therapy. Nanotechnology-driven blood-brain barrier penetration techniques are also improving drug delivery efficiency, enabling more effective glioma treatments.

What Are the Key Market Drivers?

The rising incidence of malignant gliomas, increasing research investments, and advancements in precision oncology are driving market expansion. The urgent need for therapies that improve prognosis for glioblastoma patients is encouraging biotech firms and pharmaceutical companies to develop next-generation treatment modalities.

Regulatory bodies such as the FDA and EMA are granting fast-track designations and orphan drug approvals to innovative glioma therapies, accelerating market entry for promising drugs. The expansion of clinical trial networks and patient-centric research funding is also enhancing the pipeline for new glioblastoma treatments.

Additionally, the increasing role of AI-powered diagnostics in early glioma detection and treatment planning is improving therapeutic outcomes. The integration of multi-modal treatment approaches, including a combination of immunotherapy, radiation, and precision drug delivery, is expected to drive significant advancements in glioma care.

What Challenges and Future Opportunities Exist?

Challenges include high treatment costs, drug resistance, and the complex nature of gliomas, making therapeutic development difficult. The blood-brain barrier remains a significant hurdle, limiting the effectiveness of many drugs. However, emerging nanotechnology-based drug delivery systems, AI-assisted precision oncology, and breakthrough immunotherapies present opportunities for more effective and personalized glioma treatments. Expansion into non-invasive early detection tools and AI-driven clinical decision-making could further transform the market.

SCOPE OF STUDY:

The report analyzes the Malignant Glioma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy, Glioblastoma Multiforme Immunotherapy); Drug (Temozolomide Drug, Bevacizumab Drug, Lomustine Drug, Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs); End-Use (Hospitals End-Use, Clinics End-Use, Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 35 Featured) -

  • AbbVie Inc.
  • Aivita Biomedical
  • Amgen Inc.
  • Azurity Pharmaceuticals, Inc.
  • Bayer AG
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb Company
  • Chimerix
  • Denovo Biopharma
  • Epitopoietic Research Corporation
  • F. Hoffmann-La Roche Ltd
  • Laminar Pharma
  • Merck & Co., Inc.
  • Northwest Therapeutics
  • Novocure
  • Pfizer Inc.
  • Plus Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • VBL Therapeutics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Malignant Glioma Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of High-Grade Gliomas Drives Demand for Targeted and Innovative Therapies
    • Breakthroughs in Immunotherapy and Checkpoint Inhibitors Propel Market Expansion for Glioma Treatment
    • Increased Investment in Glioma-Focused R&D Pipelines Strengthens Long-Term Market Outlook
    • Growing Adoption of Precision Oncology Drives Use of Genetic and Molecular Profiling in Glioma Cases
    • Advancements in Blood-Brain Barrier Penetrating Drug Delivery Enhance Treatment Efficacy
    • Surge in Clinical Trials for CAR-T and Oncolytic Virus Therapies Signals Future Growth Potential
    • AI-Powered Drug Discovery Platforms Accelerate Development of Novel Glioma Therapies
    • Rising Demand for Combination Therapies Drives Co-Development of Radiotherapy and Targeted Drugs
    • Improved Survival Rates with Multimodal Treatment Approaches Expand the Business Case for Innovation
    • Accelerated Approval Pathways and Orphan Drug Designations Sustain Pipeline Momentum
    • Emergence of Liquid Biopsies in Brain Cancer Monitoring Enhances Early Detection and Therapeutic Response
    • Expansion of Neurosurgical Capabilities in Emerging Markets Drives Drug Accessibility Post-Diagnosis
    • Increasing Use of Tumor-Treating Fields and Electric Field Therapy Spurs Adjunctive Therapy Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Malignant Glioma Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Malignant Glioma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Malignant Glioma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Glioblastoma Multiforme Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Glioblastoma Multiforme Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Glioblastoma Multiforme Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Glioblastoma Multiforme Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Glioblastoma Multiforme Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Glioblastoma Multiforme Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Glioblastoma Multiforme Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Glioblastoma Multiforme Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Tumor Treating Field Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Glioblastoma Multiforme Tumor Treating Field Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Glioblastoma Multiforme Tumor Treating Field Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Glioblastoma Multiforme Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Glioblastoma Multiforme Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Carmustine Wafers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Carmustine Wafers Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Carmustine Wafers Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Glioblastoma Multiforme Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Glioblastoma Multiforme Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Glioblastoma Multiforme Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Temozolomide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Temozolomide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Temozolomide Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Bevacizumab Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Bevacizumab Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Bevacizumab Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Lomustine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Lomustine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Lomustine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Malignant Glioma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Malignant Glioma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Malignant Glioma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Malignant Glioma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Malignant Glioma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Malignant Glioma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Malignant Glioma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Malignant Glioma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Malignant Glioma Therapeutics by Treatment - Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Malignant Glioma Therapeutics by Treatment - Percentage Breakdown of Value Sales for Glioblastoma Multiforme Surgery, Glioblastoma Multiforme Radiation Therapy, Glioblastoma Multiforme Chemotherapy, Glioblastoma Multiforme Targeted Therapy, Glioblastoma Multiforme Tumor Treating Field Therapy and Glioblastoma Multiforme Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Malignant Glioma Therapeutics by Drug - Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Malignant Glioma Therapeutics by Drug - Percentage Breakdown of Value Sales for Carmustine Wafers Drug, Other Glioblastoma Multiforme Drugs, Temozolomide Drug, Bevacizumab Drug and Lomustine Drug for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Malignant Glioma Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Malignant Glioma Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION